GANCICLOVIR CIDOFOVIR CMV RETINITIS TRIAL (GCCRT, ACTG 350)

这是一项关于两种治疗方案的研究，这两种方案不使用中心静脉导管就可以治疗新诊断的和复发的艾滋病相关CMV视网膜炎。这项试验的主要目的是比较最新的巨细胞病毒视网膜炎药物西多福韦与常用的治疗方案更昔洛韦眼内装置加口服更昔洛韦在预防视力丧失方面的有效性。第二个目标是比较结合了高活性局部疗法(更昔洛韦装置)的治疗方案和不含高活性局部疗法的治疗方案。进展报告和调查结果摘要：自1997年以来一直招募患者，目前共有4名活跃患者和1名死亡患者。这项IV期试验正在对FDA批准的两种治疗CMV视网膜炎的方案进行比较。两种治疗方法是：1)更昔洛韦眼内植入联合口服更昔洛韦；2)外周静脉滴注西多福韦。

This is a study of two treatment regimens that are administered without the use of a central venous catheter for both newly diagnosed and relapsed AIDS-related CMV retinitis. The primary objective of the trial is to compare the newest CMV retinitis drug, cidofovir, to a commonly used treatment regimen, the ganciclovir intraocular device plus oral ganciclovir, with respect to efficacy in preventing vision loss. A secondary objective is to compare a treatment regimen that incorporates highly active local therapy (the ganciclovir device) with a treatment regimen that does not. Progress report and summary of findings: Patients have been recruited since 1997 and there are now a total of 4 active and 1 deceased patient. This phase IV trial is in the process of comparing two FDA approved treatment regimens for CMV Retinitis. The two treatments are: 1) the ganciclovir intraocular implant plus oral ganciclovir and 2) peripherally infused cidofovir.